Bristol-Myers Squibb (BMY) return on equity (ROE)
Bristol-Myers Squibb (BMY) earned a return on equity of 38.2% in fiscal 2025 (the year ended December 31, 2025). That is 93.0 percentage points higher than the -54.8% of fiscal 2024. Figures as of 17 Nov 2026, 21:43 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- 38.2%
- Change on fiscal 2024
- +93.0 pts
- Highest on record
- 71.5%fiscal 2009
- Lowest on record
- -54.8%fiscal 2024
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Bristol-Myers Squibb return on equity (ROE), in more detail
Across the 18 fiscal years on record (2008–2025), the highest was 71.5% in fiscal 2009 and the lowest -54.8% in fiscal 2024. The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 19.5%.
Return on equity by fiscal year
Bristol-Myers Squibb return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | 38.2% | 93.0 pts up | |
| 2024 | -54.8% | 82.0 pts down | |
| 2023 | 27.3% | 6.9 pts up | |
| 2022 | 20.4% | 0.9 pts up | |
| 2021 | 19.5% | 43.3 pts up | |
| 2020 | -23.8% | 30.5 pts down | |
| 2019 | 6.7% | 28.4 pts down | |
| 2018 | 35.1% | 26.5 pts up | |
| 2017 | 8.6% | 19.0 pts down | |
| 2016 | 27.6% | 16.6 pts up | |
| 2015 | 11.0% | 2.5 pts down | |
| 2014 | 13.5% | 3.4 pts down | |
| 2013 | 16.9% | 2.5 pts up | |
| 2012 | 14.4% | 8.9 pts down | |
| 2011 | 23.2% | 3.5 pts up | |
| 2010 | 19.7% | 51.8 pts down | |
| 2009 | 71.5% | 28.6 pts up | |
| 2008 | 42.9% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| Vertex Pharmaceuticals VRTX | 21.2% | 2025 |
| Medtronic MDT | 9.7% | 2026 |
| Bristol-Myers Squibb BMY | 38.2% | 2025 |
| Stryker SYK | 14.5% | 2025 |
| McKesson MCK | 17.7% | 2020 |
| Sanofi SNY | 10.9% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Bristol-Myers Squibb, figure by figure
- Bristol-Myers Squibb market cap
- Bristol-Myers Squibb revenue
- Bristol-Myers Squibb earnings
- Bristol-Myers Squibb earnings per share (EPS)
- Bristol-Myers Squibb P/E ratio
- Bristol-Myers Squibb P/S ratio
- Bristol-Myers Squibb P/B ratio
- Bristol-Myers Squibb free cash flow
- Bristol-Myers Squibb operating margin
- Bristol-Myers Squibb dividend
- Bristol-Myers Squibb shares outstanding
- Bristol-Myers Squibb total debt
- Bristol-Myers Squibb cash on hand
- Bristol-Myers Squibb total assets
- Bristol-Myers Squibb return on invested capital (ROIC)
Bristol-Myers Squibb (BMY) overview: price, valuation and scorecardAll health care companies by market value
Bristol-Myers Squibb return on equity (ROE): questions and answers
What is Bristol-Myers Squibb's return on equity?
Bristol-Myers Squibb (BMY) earned a return on equity of 38.2% in fiscal 2025 (the year ended December 31, 2025). That is 93.0 percentage points higher than the -54.8% of fiscal 2024.
Is Bristol-Myers Squibb's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 19.5%.
What are the highest and lowest return on equity figures on record for Bristol-Myers Squibb?
Across the 18 fiscal years on record (2008–2025), the highest was 71.5% in fiscal 2009 and the lowest -54.8% in fiscal 2024.
How is Bristol-Myers Squibb's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Bristol-Myers Squibb (BMY) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BMY/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.